Barbesaclone (Epilepsy = All indications) - Medication and Pregnancy KB

Barbesaclone (Epilepsy = All indications)

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Battino (Barbexaclone) (Epilepsy) 2024	Worldwide (47 countries) 1999 - 2022 prospective cohort	The International Registry of Antiepileptic Drugs and Pregnancy (EURAP).	Pregnant women with epilepsy exposed to Barbexaclone monotherapy at the time of conception.	exposed to other treatment, sick Pregnant women with epilepsy exposed to lamotrigine monotherapy at the time of conception.	early pregnancy	23 / 3584	Overlapping/Update: Malfo as a whole: Battino 2024 (1999-2022) updates and totally includes Tomson 2018 (1999-2016), Tomson 2011 and Jimenez 2020 (1 center in Spain 2000-2018) => Use of Battino 2024 for the 8 (plus 16 in eSupp) monotherapies studied.
Battino (Barbexaclone) (Epilepsy) 2024	Worldwide (47 countries) 1999 - 2022 prospective cohort		Reporting physicians collected information on drug therapy after each trimester.		early pregnancy	23 / 3584
Canger (Barbesaclone) 1999	Italy 1977 - 1996 prospective cohort	The Epilepsy Center of the San Paolo Hospital in Milan or other in the Lombardy region.	Infants of epileptic mothers exposed to barbesaclone monotherapy during the first trimester. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Infants of epileptic mothers unexposed to antiepileptic drugs during pregnancy.	1st trimester	1 / 25	Most women gave birth at the San Paolo Hospital. Only the first pregnancies of each of the 517 women were included in the analysis.
Canger (Barbesaclone) 1999	Italy 1977 - 1996 prospective cohort		The patients received monthly obstetric and neurologic examinations, and antiepileptic drug blood levels were tested monthly.		1st trimester	1 / 25

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol